SCHEMBL16711027

SCHEMBL16711027

CC(C)(C)OC(=O)Nc1cnccc1C(F)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 3/20 0.43
▸ NAMPT P43490 1/20 0.42
▸ CYP17A1 P05093 3/20 0.40
▸ ELANE P08246 1/20 0.40
▸ CTRB1 P17538 1/20 0.40
▸ RAB9A P51151 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ BRD9 Q9H8M2 1/20 0.38
▸ CTSS P25774 1/20 0.38
▸ CTSK P43235 1/20 0.38
▸ PDE5A O76074 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE1A P54750 1/20 0.38
▸ PDE1B Q01064 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ PDE3B Q13370 1/20 0.38
▸ PDE1C Q14123 1/20 0.38
▸ PDE3A Q14432 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16711061 0.87 NAMPT (0.43) KDM4CNAMPTCYP17A1ELANECTRB1
SCHEMBL16704195 0.82 KDM4C (0.47) KDM4CRAB9A
SCHEMBL12277226 0.81 NAMPT (0.45) NAMPTCYP17A1RAB9AIDO1
SCHEMBL18522430 0.76 NAMPT (0.50) KDM4CNAMPTCYP17A1RAB9A
SCHEMBL30759207 0.75 NAMPT (0.47) KDM4CNAMPTCYP17A1RAB9A
SCHEMBL1635061 0.75 NAMPT (0.47) KDM4CNAMPTCYP17A1RAB9A
SCHEMBL18126652 0.75 RXFP1 (0.45) KDM4CNAMPTCYP17A1RAB9ABRD9
SCHEMBL23152269 0.74 NLRP3 (0.35) NAMPTCYP17A1ELANECTRB1RAB9A
SCHEMBL18126653 0.74 KDM4C (0.52) KDM4CNAMPTCYP17A1RAB9ABRD9
SCHEMBL535637 0.74 KDM4C (0.58) KDM4CNAMPTCYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809573-B2 Substituted pyridine derivatives useful as GSK-3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-11-07 — — US disclosed
US-20160289210-A1 Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-10-06 — — US disclosed
WO-2015069593-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289210-A1 Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors GSK3B, GSK3A, GRIN3A KDM4C 3060/4885NAMPT 1611/4885CYP17A1 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback